SCHEMBL5640740

SCHEMBL5640740

C=CCOc1ccc(C)cc1[N+](=O)[O-]

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.60
CYP2D6 P10635 3/20 0.60
CYP3A4 P08684 3/20 0.60
ALDH1A1 P00352 11/20 0.59
KDM4E B2RXH2 3/20 0.59
TDP1 Q9NUW8 1/20 0.59
HPGD P15428 2/20 0.57
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57
LMNA P02545 4/20 0.56
MAPT P10636 3/20 0.56
S1PR4 O95977 1/20 0.56
MAPK1 P28482 1/20 0.56
GAA P10253 1/20 0.53
AGTR1 P30556 1/20 0.51
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TSHR P16473 1/20 0.50
PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426860 0.88 ALDH1A1 (0.59) CYP1A2CYP2D6CYP3A4ALDH1A1KDM4E
SCHEMBL22579700 0.86 ALDH1A1 (0.57) CYP1A2CYP2D6CYP3A4ALDH1A1KDM4E
SCHEMBL29749978 0.83 ALDH1A1 (0.52) CYP1A2CYP2D6CYP3A4ALDH1A1KDM4E
SCHEMBL10714683 0.83 ALDH1A1 (0.52) CYP1A2CYP2D6CYP3A4ALDH1A1KDM4E
SCHEMBL28338065 0.82 CYP3A4 (0.40) CYP1A2CYP2D6CYP3A4ALDH1A1KDM4E
SCHEMBL6445803 0.82 L3MBTL1 (0.49) CYP1A2CYP2D6CYP3A4ALDH1A1KDM4E
SCHEMBL5644726 0.82 ALDH1A1 (0.50) CYP1A2CYP2D6CYP3A4ALDH1A1KDM4E
SCHEMBL17248024 0.81 CYP1A2 (0.43) CYP1A2CYP2D6CYP3A4ALDH1A1KDM4E
SCHEMBL2611830 0.81 ALDH1A1 (0.61) CYP1A2CYP2D6CYP3A4ALDH1A1KDM4E
SCHEMBL3065551 0.81 ALDH1A1 (0.52) CYP1A2CYP2D6CYP3A4ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107108586-B Polycyclic anaplastic lymphoma kinase inhibitors 山东轩竹医药科技有限公司 2020-07-10 CN disclosed
EP-3202765-B1 POLYCYCLIC ANAPLASTIC LYMPHOMA KINASE INHIBITOR HAINAN XUANZHU PHARMA CO LTD (CN) 2020-03-25 EP disclosed
US-10011592-B2 Polycyclic inhibitor of anaplastic lymphoma kinase Xuanzhu Pharma Co., Ltd. (CN) 2018-07-03 US disclosed
US-10011592-B2 Polycyclic inhibitor of anaplastic lymphoma kinase Xuanzhu Pharma Co., Ltd. (CN) 2018-07-03 US disclosed
US-10011592-B2 Polycyclic inhibitor of anaplastic lymphoma kinase Xuanzhu Pharma Co., Ltd. (CN) 2018-07-03 US disclosed
CN-104854101-B Alk kinase inhibitors 上海复尚慧创医药研究有限公司 2018-05-01 CN disclosed
US-20180086745-A9 POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2018-03-29 US disclosed
US-20180086745-A9 POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2018-03-29 US disclosed
US-20180086745-A9 POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2018-03-29 US disclosed
CN-107108586-A Polycyclic Anaplastic Lymphoma Kinase Inhibitors 山东轩竹医药科技有限公司 2017-08-29 CN disclosed
EP-2917210-A1 ALK KINASE INHIBITORS Shanghai Fochon Pharmaceutical Co. Ltd (CN) 2015-09-16 EP disclosed
WO-2014071832-A1 ALK KINASE INHIBITORS SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) 2014-05-15 WO disclosed
WO-2014071832-A1 ALK KINASE INHIBITORS SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) 2014-05-15 WO disclosed
US-20140128387-A1 CERTAIN PROTEIN KINASE INHIBITORS SHANGHAI iNSTITUTE OF MATERIA MEDICA ACADEMY OF SCIENCES (CN) 2014-05-08 US disclosed
US-20140128387-A1 CERTAIN PROTEIN KINASE INHIBITORS SHANGHAI iNSTITUTE OF MATERIA MEDICA ACADEMY OF SCIENCES (CN) 2014-05-08 US disclosed
US-20140128387-A1 CERTAIN PROTEIN KINASE INHIBITORS SHANGHAI iNSTITUTE OF MATERIA MEDICA ACADEMY OF SCIENCES (CN) 2014-05-08 US disclosed
US-7163939-B2 Macrocyclic kinase inhibitors ABBOTT LABORATORIES (US) 2007-01-16 US disclosed
EP-1682555-A1 MACROCYCLIC KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-07-26 EP disclosed
US-20050215556-A1 Macrocyclic kinase inhibitors ABBVIE INC. 2005-09-29 US disclosed
WO-2005047294-A1 MACROCYCLIC KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180086745-A9 POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE IKBKE, DCK, CHUK CYP1A2 2668/4885CYP2D6 3078/4885CYP3A4 2241/4885
US-10011592-B2 Polycyclic inhibitor of anaplastic lymphoma kinase IKBKE, DCK, CHUK CYP1A2 2668/4885CYP2D6 3078/4885CYP3A4 2241/4885
US-20140128387-A1 CERTAIN PROTEIN KINASE INHIBITORS PRKACA, PRKDC, PRKACB CYP1A2 4548/4885CYP2D6 4434/4885CYP3A4 4452/4885
US-20050215556-A1 Macrocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K7 CYP1A2 4327/4885CYP2D6 4079/4885CYP3A4 4166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.